After oesophagus, a thymus by trachea transplanters
Videregen and UCL are now making a thymus.
By Leonid Schneider, on research integrity, biomedical ethics and academic publishing
Videregen and UCL are now making a thymus.
How the Nobel Prize winner Sir Martin Evans and the lying crook Ajan Reginald almost succeeded, were it not for Patricia Murray.
The trachea-transplanting company Videregen, based in Liverpool, got another £2 million grant from UK governmental agency Innovate UK, to advance their tracheal replacement technology.
A “defamation Complaint” was lodged with Google, against 6 of my articles and one cartoon. Each of them affects to some degree the British laryngologist Martin Birchall, professor at UCL and former close associate of scandal surgeon Paolo Macchiarini. I also show that Birchall and UCL even now continue researching plastic tracheas on pigs, for future use in humans patients. This grant is presently funded by UK government.
Videregen, the Liverpool-based company which bought the trachea regeneration patent from UCL, deployed lawyers against the academics Patricia Murray and Raphael Levy, precisely via their employer University of Liverpool. Main issue is the parliamentary submission by Levy and Murray, subject to absolute privilege. Yet Videregen also cites from the confidential notice of suspected research misconduct Murray and Levy submitted in good faith to UCL.
The European Commission admitted that their €6.8 mn phase 2 clinical trial TETRA with cadaveric tracheas, led by the UCL laryngologist Martin Birchall is unlikely to ever recruit any patients. In January 2019, the status was changed to “grant agreement terminated”